Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05813327 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
A Phase 1 study of Soft Tissue Sarcoma and Sarcoma,Soft Tissue, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT05813327: Active Phase 1 study of Soft Tissue Sarcoma and Sarcoma,Soft Tissue, sponsored by Washington University School of Medicine.
NCT05813327 is a Phase 1 study of Soft Tissue Sarcoma and Sarcoma,Soft Tissue that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 6 participants, below the 79-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05813327, a Phase 1 study of Soft Tissue Sarcoma and Sarcoma,Soft Tissue, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, patients with soft tissue sarcoma (STS) will receive ADI-PEG 20 and ifosfamide in combination with radiation as neoadjuvant therapy. In phase I of the study, up to 5 dose levels will be tested to find the recommended phase II dose (RP2D), after which patients enrolling to phase II will be treated at that dose level to assess efficacy.
Primary Outcome
An adverse event is considered serious if, in the view of the investigator, it results in any of the following: * Death * A life threatening adverse event * Inpatient hospitalization or prolongation of existing hospitalization * A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions * A congenital anomaly/birth defect * Any other important medical event that does not fit the criteria above but, based upon appropriate medical judgment, ma
Conditions Studied
Interventions
- DRUG Mesna
- RADIATION Radiotherapy
- DRUG Ifosfamide
- DRUG ADI PEG20
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2024-03-14 |
| Est. Completion | 2028-05-31 |
| Phase | Phase 1 |
What the registry record for NCT05813327 still lists
NCT05813327 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 79-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (92% lower).
The record links to 3 conditions, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 4 interventions - of which Mesna is the first listed.
NCT05813327 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT05813327 about?
NCT05813327 is a clinical study titled "Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma". In this study, patients with soft tissue sarcoma (STS) will receive ADI-PEG 20 and ifosfamide in combination with radiation as neoadjuvant therapy. In phase I of the study, up to 5 dose levels will be tested to find the recommended phase II dose (RP2D), after which patients enrolling to phase II wil...
What is the current status of trial NCT05813327?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2024-03-14. Estimated completion is 2028-05-31.
What conditions does trial NCT05813327 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sts.
What interventions are being tested in trial NCT05813327?
The interventions under investigation include: Mesna (DRUG), Radiotherapy (RADIATION), Ifosfamide (DRUG), ADI PEG20 (DRUG).
Who is sponsoring clinical trial NCT05813327?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05813327 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05813327's enrollment target sits among peer trials
6 54th of 55 higher than 2 of 55 other Soft Tissue Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Soft Tissue Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
-
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
RECRUITING · Phase 1
-
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI